The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.

Manipulating brain signals called sharp wave ripples may guide the design of future treatments for memory disorders.

GlaxoSmithKline is joining forces with the University of California to dig into how gene mutations cause disease and use CRISPR to discover new drugs.

A Columbia University team has developed a CRISPR alternative that uses a bacterial “jumping gene” to insert DNA sequences.

In our EuroBiotech roundup this week, NeRRe drug fails phase 2b, Pfizer picks candidate from Sosei Heptares pact and Galapagos completes enrollment.

BlackThorn Therapeutics raised $76 million to push targeted treatments for mood disorders into phase 2 studies.

The fund sets Bain up to continue striking eye-catching deals such as the Pfizer spinouts its first life science investment vehicle bankrolled.

Medidata is being bought by France’s Dassault Systemes in a deal designed to help the tech firm diversify deeper into the biopharma services world.

The deal sees Gilead Sciences task AbCellera with using technologies to find rare antibodies with certain characteristics.